NordicRWE
- Company typePrivate
- Founded2021
- HeadquartersOslo, Norway
- Headcount1–10
- GTM typeB2B
- OfferingServices
NordicRWE firmographics
Firmographics- Name
- NordicRWE
- Legal name
- NordicRWE AS
- Website
- https://nordicrwe.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
NordicRWE industry classification
Industry- Product category
- Real-world Evidence Services for Pharmaceutical R&D
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)
- akta.pro secondary industries
- Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK), Real-World Evidence (RWE) & Outcomes Analytics for Precision Therapies (HLAAANAJ), Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)
Keywords
Where NordicRWE is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices3 records
Markets served
NordicRWE business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- RWE Research Services: Full-service RWE research collaborations with biopharma companies, handling projects from initial study concept discussions to final reporting. Services span all therapeutic areas and support the entire RWE value chain including epidemiology studies, trial emulation, and regulatory submissions.
- R&D Project Collaboration: Collaborative R&D projects supported by public research grants and customer-funded research, focused on oncology external control arms, drug signal detection, and AI applications in RWE analytics.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
NordicRWE product offering
Product offeringCore offering
NordicRWE is a full-service Real-world Evidence (RWE) research provider that delivers data-driven drug development support to biopharma companies. It leverages mandatory, population-based Nordic health registries covering 27 million inhabitants to build external control arms, emulate clinical trials, and run drug signal detection studies. Engagements are project-based, spanning the full RWE value chain from study concept through final reporting across all therapeutic areas.
Product overview
NordicRWE is a dedicated Real-world Evidence (RWE) company offering a portfolio of solutions that leverage the unique Nordic health data infrastructure. The core offerings include Oncology External Control Arms and Emulation Studies for cancer drug development, Drug Signal Detection combining machine learning with pharmacoepidemiological validation, and AI and Language Models in RWE Analytics that adapt LLMs to health data. Supporting modules include Interactive Dashboard Solutions for visualizing research findings and Synthetic Data Generation for feasibility assessments. The company also provides full-service Customer RWE Research Collaboration handling projects from concept to reporting across all therapeutic areas. Two major R&D programs - RWE Accelerate (Norwegian Research Council funded) and Biobank Norway Collaboration - drive innovation in target trial emulation and molecular profiling respectively.
Differentiator
Problem solved
Functional benefit
Products and services
- Oncology External Control Arms and Emulation Studies Real-world evidence solutions that construct external control arms (ECA) for single-arm oncology trials and emulate randomized controlled trial populations using Nordic health data to support drug development and regulatory decision-making. Currently focused on lung, breast, and ovarian cancers.
- Drug Signal Detection A data-driven drug discovery and surveillance platform combining machine learning hypothesis generation with rigorous pharmacoepidemiological validation using longitudinal real-world data. Focus areas include dementia drug repurposing and side-effect signal detection of lipid-modifying drugs.
- AI and Language Models in RWE Analytics Advanced AI research program adapting large language models and generative AI to real-world evidence research, converting patient registry data into 'life sequences' (temporally structured text formats) so AI models can learn from longitudinal Nordic health data as narratives of care, treatments, diagnoses, and outcomes.
- Customer RWE Research Collaboration Full-service real-world evidence research engagement handling customer projects from initial study concept discussions through final reporting, supporting the entire RWE value chain across all therapeutic areas including external control arms, disease epidemiology studies, and target trial emulation.
- Interactive Dashboard Solutions Project-specific interactive dashboards providing high-value evidence and timely insights about patient journeys, supporting market access documentation, clinical development, and pipeline decisions.
- Synthetic Data Generation Synthetic data generation and utilization for feasibility assessments and data exploration, developed in collaboration with the Cancer Registry of Norway and used in both internal R&D projects and external collaborations.
Quantifiable outcome
- RWE Accelerate project funded by Research Council of Norway (grant no. 327887) for October 2021 to December 2025
- +2 more outcomes
Companies that use NordicRWE
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
NordicRWE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature7 records
NordicRWE partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Department of Biostatistics, University of OslocoreAcademic partner in the RWE Accelerate project, providing biostatistics expertise for developing methodology to turn Nordic health data infrastructure into products and services for drug development acceleration. The project runs from October 2021 to December 2025.
- Department of Registry Informatics, Cancer Registry of NorwaycorePartner in the RWE Accelerate project providing registry informatics expertise and access to cancer registry data for external control arms and target trial emulation research.
- Biobank Norway (bbmri.no)coreCollaboration with the national research infrastructure for human biobanks in Norway to perform molecular profiling on archived tumor tissue samples in hospital biobanks. Addresses the data gap for biomarker information in novel biomarker-directed oncology drugs not yet implemented in clinical practice.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
NordicRWE competitors and assessment
Company assessmentBroad incumbents
- IQVIA: Global leader in RWE, HEOR, and clinical research services with massive proprietary data assets. Direct competitor for enterprise RWE engagements but at vastly larger scale and broader therapeutic and geographic reach.
- ICON plc: Global CRO with RWE capabilities post-PRA Health Sciences integration. Competes with NordicRWE for RWE studies within broader clinical research engagements but at a much larger scale.
- Evidera: RWE and HEOR consulting business within the PPD/Thermo Fisher CRO franchise. Comparable as a full-service RWE/HEOR provider to biopharma, but operating as part of a global CRO with broader service breadth.
Direct peers
- Flatiron Health: Oncology-specific real-world evidence and electronic medical record company serving biopharma. Direct comparable given NordicRWE's oncology external control arm focus, with similar customer base (large biopharma) and similar ECA / trial emulation productization.
- Truveta: Real-world data platform aggregating de-identified EHR data from US health systems for biopharma research. Comparable as an enterprise RWE data-and-analytics vendor targeting pharma drug development and regulatory use cases.
- ConcertAI: Oncology-focused real-world data and AI company serving biopharma and providers. Direct comparable given NordicRWE's oncology ECA emphasis and similar AI-on-RWD technology positioning.
- TriNetX: Global federated health data network providing real-world data access for clinical research and trial design. Highly comparable to NordicRWE's registry-based RWE platform approach, though TriNetX relies on a federated EHR network rather than a single national registry system.
- Tempus Labs: AI-driven precision medicine company combining multimodal real-world clinical and molecular data for pharma R&D. Comparable on the AI-on-real-world-data thesis and oncology depth, though Tempus operates at much larger scale.
- Aetion: RWE analytics platform used by biopharma and regulators to evaluate treatments using real-world data. Comparable as an enterprise RWE analytics vendor, though Aetion is platform/SaaS-led whereas NordicRWE combines data assets with services.
Emerging players
- Owkin: AI-for-biopharma company applying federated learning and AI to clinical and real-world data. Comparable on the AI-on-real-world-data theme for pharma R&D, though Owkin focuses on pathology and multimodal AI rather than registry-based RWE.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
NordicRWE social profiles
Digital presenceNordicRWE financial estimates
Financial estimateRevenue estimate
Valuation estimate
NordicRWE leadership team
Management profileNumber of profiles
Profiles10 records
NordicRWE funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NordicRWE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NordicRWE
What does NordicRWE do?
NordicRWE is a full-service Real-world Evidence (RWE) research provider that delivers data-driven drug development support to biopharma companies. It leverages mandatory, population-based Nordic health registries covering 27 million inhabitants to build external control arms, emulate clinical trials, and run drug signal detection studies. Engagements are project-based, spanning the full RWE value chain from study concept through final reporting across all therapeutic areas.
Is NordicRWE a public or private company?
NordicRWE is a private company. It is classified as unknown and is currently operating.
When was NordicRWE founded?
NordicRWE was founded in 2021. It employs 1 to 10 people.
Where is NordicRWE based?
NordicRWE is headquartered in Oslo, Norway, in the Europe region.
How does NordicRWE make money?
Two revenue lines are on record. RWE Research Services are the primary driver. The others are R&D Project Collaboration.
Who are NordicRWE's main competitors?
Broad incumbents on record are IQVIA, ICON plc and Evidera. Direct peers are Flatiron Health, Truveta, ConcertAI, TriNetX, Tempus Labs and Aetion. Owkin is listed as an emerging player.
Does NordicRWE have an API?
No public API is recorded for NordicRWE.
What industry is NordicRWE in?
NordicRWE's product category is Real-world Evidence Services for Pharmaceutical R&D. Its primary akta.pro industry code is BPAHALAN, Healthcare Outcomes & Real-World Evidence (RWE) Analytics, with a secondary code of HLAGAAAK, Real-World Evidence (RWE), HEOR & Epidemiology CROs. Its NAICS code is 5417 and its SIC code is 8731.